Summary
The Sleep Disorders Partnering 2007-2013 report provides understanding and access to the sleep disorders partnering deals and agreements entered into by the worlds leading healthcare companies.
The Psychiatry Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the psychiatry partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of How and why companies enter psychiatry partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors psychiatry technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of How payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 1,000 links to online copies of actual psychiatry deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of psychiatry dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in psychiatry dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading psychiatry deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of psychiatry deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of psychiatry partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), technology type and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in psychiatry partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of psychiatry technologies and products.
Report scope
Psychiatry Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to psychiatry trends and structure of deals entered into by leading companies worldwide.
Psychiatry Partnering Terms and Agreements includes:
The Psychiatry Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,000 psychiatry deals. Analyzing actual contract agreements allows assessment of the following:
Psychiatry Partnering Terms and Agreements provides the reader with the following key benefits:
The Sleep Disorders Partnering 2007-2013 report provides understanding and access to the sleep disorders partnering deals and agreements entered into by the worlds leading healthcare companies.
- Trends in sleep disorders partnering deals
- Top sleep disorders deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type
The Psychiatry Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the psychiatry partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of How and why companies enter psychiatry partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors psychiatry technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of How payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 1,000 links to online copies of actual psychiatry deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of psychiatry dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in psychiatry dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading psychiatry deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of psychiatry deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of psychiatry partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), technology type and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in psychiatry partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of psychiatry technologies and products.
Report scope
Psychiatry Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to psychiatry trends and structure of deals entered into by leading companies worldwide.
Psychiatry Partnering Terms and Agreements includes:
- Trends in psychiatry dealmaking in the biopharma industry since 2007
- Analysis of psychiatry deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life psychiatry deals
- Access to over 1,000 psychiatry deal records
- The leading psychiatry deals by value since 2007
- Most active psychiatry dealmakers since 2007
- The leading psychiatry partnering resources
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
The Psychiatry Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,000 psychiatry deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Psychiatry Partnering Terms and Agreements provides the reader with the following key benefits:
- In-depth understanding of psychiatry deal trends since 2007
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to over 1,000 actual psychiatry contracts entered into by the world’s biopharma companies
- Detailed access to actual psychiatry contracts enter into by the leading fifty bigpharma companies
- Insight into the terms included in a psychiatry agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
EXECUTIVE SUMMARY
CHAPTER 1 – INTRODUCTION
CHAPTER 2 – TRENDS IN PSYCHIATRY DEALMAKING
2.1. Introduction
2.2. Psychiatry partnering over the years
2.3. Bigpharma psychiatry dealmaking activity
2.4. Bigpharma not active in psychiatry
2.5. Psychiatry partnering by deal type
2.6. Psychiatry partnering by industry sector
2.7. Psychiatry partnering by stage of development
2.8. Psychiatry partnering by technology type
2.9. Psychiatry partnering by oncology indication
2.10. Average deal terms for psychiatry
2.10.1 Psychiatry headline values
2.10.2 Psychiatry upfront payments
2.10.3 Psychiatry milestone payments
2.10.4 Psychiatry royalty rates
CHAPTER 3 – LEADING PSYCHIATRY DEALS
3.1. Introduction
3.2. Top psychiatry deals by value
3.3. Top psychiatry deals involving bigpharma
CHAPTER 4 – BIGPHARMA PSYCHIATRY DEALS
4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Bigpharma psychiatry partnering company profiles
Abbott
Actavis
Alcon Labs
Allergan
Amgen
Apotex
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Cephalon
Chugai
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Roche
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB
Warner Chilcott
Watson
CHAPTER 5 – DEALMAKING DIRECTORY
5.1. Introduction
5.2. By company A-Z
5.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Development
Distribution
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Supply
Technology transfer
5.4. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
5.5. By technology type
Adjuvant
Analysis
Animal models
Assays
Biodefense
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Bioprocessing
Biosimilars/Bio-betters
Blood products
Cell culture
Cell therapy
Clinical testing
Diagnostic – companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Glycomics
Imaging
Implant
In vitro models
Microarray
Monoclonal antibodies
Nanotechnology
Natural product
Oligonucleotide
Orphan drug
Packaging
Pediatrics
Peptides
Personalised medicine
Pharmacogenomics
Processes
Proteomics
Radio/Chemo-therapy
Rational drug design
Recombinant DNA
Regenerative medicine
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Software tools
Stem cells
Toxicity
Transgenics
Vaccines
5.6. By therapeutic indication
Psychiatry
Anxiety disorder
Generalised anxiety disorder
Panic disorder
Post traumatic stress disorder
Attention deficit hyperactivity disorder
Bipolar disorder
Chronic fatigue syndrome
Cognitive impairment
Dementia
Alzheimers
Dementia with lewy bodies
Depression Autism
Mania
Obsessive compulsive disorder
Schizophrenia
Sleep disorders
CHAPTER 6 – PARTNERING RESOURCE CENTER
6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking
APPENDICES
Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
TABLE OF FIGURES
Figure 1: Cardiovascular partnering since 2007
Figure 2: Bigpharma – top 50 – cardiovascular deals 2007 to 2011
Figure 3: Bigpharma cardiovascular deal frequency – 2007 to 2011
Figure 4: Inactive bigpharma in cardiovascular 2007-2011
Figure 5: Cardiovascular partnering by deal type since 2007
Figure 6: Cardiovascular partnering by industry sector since 2007
Figure 7: Cardiovascular partnering by stage of development since 2007
Figure 8: Cardiovascular partnering by technology type since 2007
Figure 9: Cardiovascular partnering by oncology target since 2007
Figure 10: Cardiovascular deals with a headline value
Figure 11: Cardiovascular deal headline value distribution, US$million – discovery stage
Figure 12: Cardiovascular deal headline value distribution, US$million – preclinical stage
Figure 13: Cardiovascular deal headline value distribution, US$million – phase I stage
Figure 14: Cardiovascular deal headline value distribution, US$million – phase II stage
Figure 15: Cardiovascular deal headline value distribution, US$million – phase III stage
Figure 16: Cardiovascular deal headline value distribution, US$million – regulatory stage
Figure 17: Cardiovascular deal headline value distribution, US$million – marketed stage
Figure 18: Summary median headline value by stage of development, 2007-2011
Figure 19: Cardiovascular deals with upfront payment values
Figure 20: Cardiovascular deal upfront payment distribution, US$million – discovery stage
Figure 21: Cardiovascular deal upfront payment distribution, US$million – preclinical stage
Figure 22: Cardiovascular deal upfront payment distribution, US$million – phase I stage
Figure 23: Cardiovascular deal upfront payment distribution, US$million – phase II stage
Figure 24: Cardiovascular deal upfront payment distribution, US$million – phase III stage
Figure 25: Cardiovascular deal upfront payment distribution, US$million – regulatory stage
Figure 26: Cardiovascular deal upfront payment distribution, US$million – marketed stage
Figure 27: Summary median upfront payments by stage of development, 2007-2011
Figure 28: Cardiovascular deals with milestone payments
Figure 29: Cardiovascular deals with royalty rates, %
Figure 30: Cardiovascular deal royalty rate distribution, US$million – discovery stage
Figure 31: Cardiovascular deal royalty rate distribution, US$million – preclinical stage
Figure 32: Cardiovascular deal royalty rate distribution, US$million – phase I stage
Figure 33: Cardiovascular deal royalty rate distribution, US$million – phase II stage
Figure 34: Cardiovascular deal royalty rate distribution, US$million – phase III stage
Figure 35: Cardiovascular deal royalty rate distribution, US$million – regulatory stage
Figure 36: Cardiovascular deal royalty rate distribution, US$million – marketed stage
Figure 37: Summary median royalty rate by stage of development, 2007-2011
Figure 38: Top cardiovascular deals by value since 2007
Figure 39: Top cardiovascular deals signed by bigpharma value since 2007
Figure 40: Online partnering resources
Figure 41: Forthcoming partnering events
Figure 42: Deal type definitions
CHAPTER 1 – INTRODUCTION
CHAPTER 2 – TRENDS IN PSYCHIATRY DEALMAKING
2.1. Introduction
2.2. Psychiatry partnering over the years
2.3. Bigpharma psychiatry dealmaking activity
2.4. Bigpharma not active in psychiatry
2.5. Psychiatry partnering by deal type
2.6. Psychiatry partnering by industry sector
2.7. Psychiatry partnering by stage of development
2.8. Psychiatry partnering by technology type
2.9. Psychiatry partnering by oncology indication
2.10. Average deal terms for psychiatry
2.10.1 Psychiatry headline values
2.10.2 Psychiatry upfront payments
2.10.3 Psychiatry milestone payments
2.10.4 Psychiatry royalty rates
CHAPTER 3 – LEADING PSYCHIATRY DEALS
3.1. Introduction
3.2. Top psychiatry deals by value
3.3. Top psychiatry deals involving bigpharma
CHAPTER 4 – BIGPHARMA PSYCHIATRY DEALS
4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Bigpharma psychiatry partnering company profiles
Abbott
Actavis
Alcon Labs
Allergan
Amgen
Apotex
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Cephalon
Chugai
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Roche
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB
Warner Chilcott
Watson
CHAPTER 5 – DEALMAKING DIRECTORY
5.1. Introduction
5.2. By company A-Z
5.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Development
Distribution
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Supply
Technology transfer
5.4. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
5.5. By technology type
Adjuvant
Analysis
Animal models
Assays
Biodefense
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Bioprocessing
Biosimilars/Bio-betters
Blood products
Cell culture
Cell therapy
Clinical testing
Diagnostic – companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Glycomics
Imaging
Implant
In vitro models
Microarray
Monoclonal antibodies
Nanotechnology
Natural product
Oligonucleotide
Orphan drug
Packaging
Pediatrics
Peptides
Personalised medicine
Pharmacogenomics
Processes
Proteomics
Radio/Chemo-therapy
Rational drug design
Recombinant DNA
Regenerative medicine
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Software tools
Stem cells
Toxicity
Transgenics
Vaccines
5.6. By therapeutic indication
Psychiatry
Anxiety disorder
Generalised anxiety disorder
Panic disorder
Post traumatic stress disorder
Attention deficit hyperactivity disorder
Bipolar disorder
Chronic fatigue syndrome
Cognitive impairment
Dementia
Alzheimers
Dementia with lewy bodies
Depression Autism
Mania
Obsessive compulsive disorder
Schizophrenia
Sleep disorders
CHAPTER 6 – PARTNERING RESOURCE CENTER
6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking
APPENDICES
Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
TABLE OF FIGURES
Figure 1: Cardiovascular partnering since 2007
Figure 2: Bigpharma – top 50 – cardiovascular deals 2007 to 2011
Figure 3: Bigpharma cardiovascular deal frequency – 2007 to 2011
Figure 4: Inactive bigpharma in cardiovascular 2007-2011
Figure 5: Cardiovascular partnering by deal type since 2007
Figure 6: Cardiovascular partnering by industry sector since 2007
Figure 7: Cardiovascular partnering by stage of development since 2007
Figure 8: Cardiovascular partnering by technology type since 2007
Figure 9: Cardiovascular partnering by oncology target since 2007
Figure 10: Cardiovascular deals with a headline value
Figure 11: Cardiovascular deal headline value distribution, US$million – discovery stage
Figure 12: Cardiovascular deal headline value distribution, US$million – preclinical stage
Figure 13: Cardiovascular deal headline value distribution, US$million – phase I stage
Figure 14: Cardiovascular deal headline value distribution, US$million – phase II stage
Figure 15: Cardiovascular deal headline value distribution, US$million – phase III stage
Figure 16: Cardiovascular deal headline value distribution, US$million – regulatory stage
Figure 17: Cardiovascular deal headline value distribution, US$million – marketed stage
Figure 18: Summary median headline value by stage of development, 2007-2011
Figure 19: Cardiovascular deals with upfront payment values
Figure 20: Cardiovascular deal upfront payment distribution, US$million – discovery stage
Figure 21: Cardiovascular deal upfront payment distribution, US$million – preclinical stage
Figure 22: Cardiovascular deal upfront payment distribution, US$million – phase I stage
Figure 23: Cardiovascular deal upfront payment distribution, US$million – phase II stage
Figure 24: Cardiovascular deal upfront payment distribution, US$million – phase III stage
Figure 25: Cardiovascular deal upfront payment distribution, US$million – regulatory stage
Figure 26: Cardiovascular deal upfront payment distribution, US$million – marketed stage
Figure 27: Summary median upfront payments by stage of development, 2007-2011
Figure 28: Cardiovascular deals with milestone payments
Figure 29: Cardiovascular deals with royalty rates, %
Figure 30: Cardiovascular deal royalty rate distribution, US$million – discovery stage
Figure 31: Cardiovascular deal royalty rate distribution, US$million – preclinical stage
Figure 32: Cardiovascular deal royalty rate distribution, US$million – phase I stage
Figure 33: Cardiovascular deal royalty rate distribution, US$million – phase II stage
Figure 34: Cardiovascular deal royalty rate distribution, US$million – phase III stage
Figure 35: Cardiovascular deal royalty rate distribution, US$million – regulatory stage
Figure 36: Cardiovascular deal royalty rate distribution, US$million – marketed stage
Figure 37: Summary median royalty rate by stage of development, 2007-2011
Figure 38: Top cardiovascular deals by value since 2007
Figure 39: Top cardiovascular deals signed by bigpharma value since 2007
Figure 40: Online partnering resources
Figure 41: Forthcoming partnering events
Figure 42: Deal type definitions
